Black Diamond Therapeutics’ (BDTX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX – Free Report) in a report issued on Wednesday,Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright also issued estimates for Black Diamond Therapeutics’ Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.29) EPS, Q1 2025 […]
9 Nov 15:24 · The Markets Daily